STEMI Clinical Trial
— PromiseOfficial title:
A Retrospective, One Center Comparison of Outcomes Between Complete Revascularization by PCI at the Time of PPCI or During the Index Hospital Admission in One Hundred MVD Patients With ST-elevation MI Uncomplicated by Cardiogenic Shock
NCT number | NCT04582175 |
Other study ID # | Uoradea |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | July 1, 2020 |
Est. completion date | September 5, 2020 |
Verified date | October 2020 |
Source | University of Oradea |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The study aimed to compare major adverse cardiac and cerebrovascular events(MACCE) and mortality at one year between two strategies: complete revascularization including non-culprit lesions percutaneous coronary intervention(PCI) during primary PCI(PPCI) versus complete revascularisation during the same hospital admission in multi-vascular coronary artery disease(MVD) patients presenting with ST-elevation myocardial infarction(STEMI) uncomplicated by cardiogenic shock.
Status | Completed |
Enrollment | 100 |
Est. completion date | September 5, 2020 |
Est. primary completion date | September 1, 2020 |
Accepts healthy volunteers | |
Gender | All |
Age group | 18 Years to 90 Years |
Eligibility |
Inclusion Criteria: 1. Men and women with successful PCI (preferably using a drug-eluting stent) to the culprit lesion for STEMI ( PCI for STEMI should be primary PCI in the first 12 hours after symptom onset) and complete revascularization of non-culprit lesions during the index PPCI procedure or during a different procedure performed before index hospital discharge. 2. Multi-vessel disease defined as at least 1 additional non-infarct related coronary artery lesion that is at least 2.5 mm in diameter that has not been stented as part of the primary PCI and that is amenable to successful treatment with PCI and has: - At least 75% diameter stenosis (visual estimation) or - At least 50% diameter stenosis (visual estimation) with fractional flow reserve (FFR) = 0.80 3. Age between 18 and 90 years 4. Written informed consent could be obtained from all the patients Exclusion Criteria: 1. Rescue PCI for failed fibrinolysis or a combination strategy where PCI is performed routinely 3-12 hours after fibrinolysis 2. Cardiogenic shock 3. Non-cardiovascular known co-morbidity reducing life expectancy to < 2 years 4. Any factor precluding 1year follow-up 5. Prior Coronary Artery Bypass Graft (CABG) Surgery 6. A different operator from the previously designated 7. Unable to provide consent for any other reason |
Country | Name | City | State |
---|---|---|---|
Romania | Spitalul Clinic Judetean de Urgenta Oradea | Oradea | Bihor |
Lead Sponsor | Collaborator |
---|---|
University of Oradea |
Romania,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | one year all-cause mortality | death at one year | one year | |
Primary | MACCE at one year | major adverse cardiac and cerebrovascular events including cardiac death, stroke, symptom-driven revascularization, myocardial infarction | one year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT02871622 -
BMX Alpha Registry: a Post-market Registry of the BioMatrix Alpha TM
|
N/A | |
Completed |
NCT01452139 -
Pharmacogenetic Approach to Anti-platelet Therapy for the Treatment of ST-segment Elevation Myocardial Infarction (STEMI)
|
Phase 2/Phase 3 | |
Completed |
NCT01325116 -
Delayed Educational Reminders in Acute Myocardial Infarction (MI)
|
N/A | |
Completed |
NCT01625104 -
Randomized Trial of a Quality Improvement Intervention to Decrease D2B Time in Primary PCI for AMI
|
N/A | |
Completed |
NCT04023266 -
A Pilot Randomized Controlled Trial of Intravenous N-acetyl Cysteine in STEMI
|
Phase 2 | |
Completed |
NCT02170103 -
Microvascular Recovery With Ultrasound in Myocardial Infarction (MRUSMI) Post PCI Trial
|
N/A | |
Completed |
NCT03103620 -
Safety and Effectiveness Evaluation of COBRA PzF Coronary Stent System: A Post Marketing Observational Registry
|
||
Not yet recruiting |
NCT05975567 -
Deploying Novel Imaging Modalities Towards a Three-dimensional (3D) CARDIOvascular PATHology
|
||
Enrolling by invitation |
NCT03328156 -
Erectile Dysfunction After Percutaneous Coronary Intervention Versus the Thrombolytic Therapy in Acute ST Elevation Myocardial Infarction
|
N/A | |
Completed |
NCT04017169 -
No Reflow Phenomenon Incidence and Predictors
|
||
Completed |
NCT03470441 -
A Study of Acute Myocardial Infarction Using FDY-5301
|
Phase 2 | |
Active, not recruiting |
NCT01433627 -
Minimizing Adverse Haemorrhagic Events by TRansradial Access Site and Systemic Implementation of angioX
|
Phase 3 | |
Completed |
NCT01197742 -
Sweetheart-Register: Risk Management of Diabetics With Acute Myocardial Infarction
|
N/A | |
Terminated |
NCT03439150 -
Resistance STEMI Study
|
N/A | |
Recruiting |
NCT03998319 -
A Study of Low-dose Intracoronary Thrombolytic Therapy in STEMI (Heart Attack) Patients.
|
Phase 3 | |
Not yet recruiting |
NCT05974930 -
Intravascular ULTRAsound-Guided PCI in Patients With ST-Elevation Myocardial Infarction
|
||
Active, not recruiting |
NCT03102723 -
Platelet Inhibition to Target Reperfusion Injury
|
Phase 2 | |
Completed |
NCT03930589 -
Remote Ischemic Conditioning in STEMI to Decrease Infarct Size
|
N/A | |
Not yet recruiting |
NCT04912167 -
The Effects of Sacubitril-Valsartan vs Enalapril on Left Ventricular Remodeling in ST-elevation Myocardial Infarction
|
Phase 3 | |
Completed |
NCT02942550 -
Methylnaltrexone as a Method to Improve Ticagrelor Uptake in Morphine Treated STEMI Patients
|
Phase 4 |